As former President Donald Trump’s legal woes mount, the line between his criminal defense and his 2024 presidential campaign is blurring, a political and financial muddying that The Washington Post projects will only worsen as
Nicholas J has ruled that ToolGen’s application for a patent, AU 2013335451, for “what is now a well-known gene editing system known as the CRISPR/Cas9 system” for editing target DNZ sequences in eukaryotic cells. His Honor has allowed ToolGen until
The Justice Department and the Federal Trade Commission on Wednesday released a set of long-anticipated draft updates to the nation’s merger guidelines, introducing potentially comprehensive changes to the way the US government reviews mergers and acquisitions for the
Changes may be coming to the “de minimis” exception under Section 321 of the Tariff Act of 1930, as amended, which allows goods valued less than $800 to enter the United States free of duty and taxes, and generally free
This appeal relates to the interpretation of the Immigration Rules, in particular the Tier 1 (Investor) Migrant regime (as in force in December 2017 – it has since been closed). This regime was designed to grant leave to remain to
Democratic lawmakers on Thursday weighed in on former President Trump’s indictment in connection with an investigation into his handling of classified documents, with many arguing that the news shows the former president and current 2024 candidate isn’t above the law.